Our 12-month target price of $74, cut $44, reflects our updated discounted cash flow model analysis. We widen our expected '22 loss per share by $0.02 to $0.81 but narrow '23's by $0.07 to $0.13. Q1 loss per share of $0.38, vs. $0.11, was $0.04 wider than the consensus view. Revenues in Q1 were $114 million, up 8% year over year, but the pace was markedly improved in March after a slow start in January and February (which TXG believes was Omicron-driven). TXG reiterated revenue guidance in the $600m - $630m range for '22, although we think lockdowns in China represent a significant wild card. The company said it expects the lockdowns to end by mid-May, but our confidence in that timing is low. Longer term, we think customer uptake from new platforms should be strong, but near-term growth rates may be relatively slower.
|Tango Therapeutics Added to Russell 2000, Russell 30...|
|Origin Materials to be Added to Russell 2000, 3000 I...|
|Market Chatter: Alphabet's Google Faces Antitrust Co...|
|EVgo Says it is Being Added to Russell 3000, Russell...|
|Mizuho Securities Adjusts Tesla's Price Target to $1...|